WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD.Can-Fite BioPharma Ltd. • December 23rd, 2021 • Pharmaceutical preparations • New York
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the fifth-year anniversary of the date on which an initial resale registration statement registering the Warrant Shares issuable upon the exercise of the Warrants becomes effective by the Commission (the “Termination Date”) but not thereafter, to subscribe for and purchase from Can-Fite BioPharma Ltd., an Israeli limited company (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by ________1 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to t
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • December 23rd, 2021 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of December 20, 2021, is by and between Can-Fite BioPharma Ltd., an Israeli company (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of Series A warrants to purchase ordinary shares of the Company, par value NIS 0.25 per share (the “Ordinary Shares”), represented by American Depositary Shares issued by the Company, which warrants were issued on August 16, 2021 and are exercisable at an exercise price of $2.00 per ADS, (the “Original Warrants”).
